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SUMMARY
Intracavernosal injectionofpapaverineandphentolamine wasused in20patients
with impotence. After sLx months 14 patients were still using the self-injection
treatment. Two patients failed to respond and two patients developed priapism
which responded to venesection and metaraminol injection.
INTRODUCTION
Intracavernosal injection of the penis is the most effective medical treatment for
impotence. While some of the original studies used phenoxybenzamine,1 the
most common treatment at present is with papaverine or phentolamine, either
alone or in combination.2-7 Papaverine (a smooth muscle relaxant) or phento-
lamine (an alpha-blocker) can increase penile tumescence and produce an
erection after injection into the corpus cavernosum; unilateral injection produces
bilateral engorgement due to cross circulation. When these drugs are injected
arterial inflow increases and venous outflow decreases, probably due to
relaxation of the corporeal smooth muscle with occlusion of the venules.
Previous studies have advocated the use of this treatment in impotence both of
an organic and a psychological nature. This paper presents the results ofthe first
20 patients treated at the Department of Genitourinary Medicine, and it aims
to assess the effect of these drugs, complications, acceptability and practical
problems associated with this therapy.
PATIENTS AND METHODS
Patients presenting to this clinic with impotence, either total or partial, are
encouraged to attend with their regular partner and are seen by appointment.
After a sexual and medical history and examination the treatment options are
explained. These include referral for psychotherapy, intra -cavernosal injection,
mechanical aids to erection and surgery. All patients have routine tests for
haemoglobin concentration, plasma glucose, testosterone, prolactin, liver
function and hepatitis antigen.
Patients electing for intracavernosal injection have the possible complications
explained and give signed consent for therapy. In addition they are given a list of
potential complications and written instructions for the self-injection technique.
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An initial test dose of papaverine 30 mg and phentolamine 1 mg is given in the
lateral aspect of the corpus cavernosum using a 2 ml syringe with a fine bore
needle (26 gauge, 0 45 x 13 mm dental needle) at a site 1-2 cm proximal to
the coronal sulcus of the penis with constriction of the base of the penis either
manually or using a rubber band as a tourniquet. The drugs are combined in a
single ampoule by the pharmaceutical department of the Royal Victoria Hospital
and have an expiry date of approximately six months (note: phentolamine
normally is available in vials containing 10 mg in 1 ml and the most convenient
method of measurement is to withdraw 0 1 ml of phentolamine using an insulin
syringe and transfer to a 2 ml syringe which is then used to draw the papaverine
30 mg in 2 ml). Response with erection is normally in 20-30 minutes and during
this period patients have regular pulse rate and blood pressure measurements
recorded at 10 minute intervals. Patients who fail to respond are given higher
doses at later consultations, up to 90 mg papaverine and 3 mg phentolamine.
Patients with a prolonged response, eg three to four hours duration, will be given
a reduced dose at subsequent injections. The lowest effective dose is always
used. After erection patients are allowed home. They are always given the home
phone number of the supervising doctor, warned about the potential risk of
priapism and instructed to present themselves earlythe following morning should
this complication develop. Once the effective dose is attained patients inject
themselves under medical supervision and, if this is successful, they are given a
supply of needles, syringes and prepared ampoules containing phentolamine and
papaverine for three occasions and are reviewed two weeks later. If there are no
complications they are reviewed at two to three monthly intervals for a check
-up
and renewal of drug supplies.
RESULTS
The average age of the first 20 patients treated was 47*6 years (range 32 -72).
Seven had psychogenic or anxiety symptoms, 10 physical or mixed psychogenic
and physical symptoms, and in three theimpotence wasjudged to be of idiopathic
origin. Fourteen patients were still using injection therapy at the end of six
months. A total of six patients discontinued treatment, two due to priapism, one
due to bruising, two due to incomplete injection response and one who gave no
reason. The duration of erection in the patients who continued treatment was
between 30 minutes and three hours with a median of two hours. The dosages
used were papaverine 30 mg and phentolamine 1 mg in 18 patients, one patient
used papaverine 15 mg and phentolamine 0
-5 mg. In one patient treatment was
unsuccessful at a dose level of papaverine 75 mg and phentolamine 2*5 mg.
The treatment of priapism is as follows: a 19 gauge cannula is inserted into the
corpus cavernosum of the penis and blood allowed to flow into a dish for 10-15
minutes. Onemg metaraminol isdrawn up in an insulin syringe and diluted to 1 ml
with normal saline. A further 10 ml of normal saline is drawn into a separate
syringe. When the penis is compressible the metaraminol is injected and followed
with 10 ml normal saline, with simultaneous penile massage. Up to 60-80 ml of
blood is aspirated, and the penis should at this stage be flaccid. In one patient this
procedure was repeated twice before relief.
DISCUSSION
Injection with phentolamine and papaverine produced an erection sufficient for
intercourse in 18 of the 20 subjects. In two there was only a partial response,
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reported by others.3-7 Although priapism developed in two it was easily relieved
with metaraminol.A 9 It is essential that the doctor prescribing therapy makes
himself available directly to the patient especially following the first and second
doses as this is when priapism is most likely to occur. One patient felt a small
fibrous nodule in the penis which resolved when treatment was stopped. Similar
nodules have been described byAbozeid10after 100 intracavemosal injections in
each ofsix Macaca monkeys and Hu1I hasconfirmed in humans thatthis may be
related to injection into the tunica albuginea. Patients are instructed to insert the
needle until they feel a characteristic "give" asthe needle penetrates the tunica of
the corpus cavernosum, but this did not prevent the complication in one patient.
Only 14 ofthe original 20 subjects were still on therapy atthe end ofsix months,
butthis comparesfavourably withthe 60-80% ofpatients who continue therapy
reported from other centres.2-7 These patients (most of whom are not diabetic
and not used to injections) found the technique of self-injection easy to master,
and no patient discontinued therapy because of injection discomfort.
This new method of therapy seems suitable for patients with an organic cause of
impotence, but in elderly patients there is a less certain result and this may be
due to related vascular disease. The method may be helpful in some cases of
psychogenic impotence. However, in these cases it does not supplant the role of
psychosexual therapy but may be used as an adjunct in unresponsive cases. In
those considering penile implants intracavernosal injections clearly should be
discussed before surgery is undertaken.
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